Loris Zamai / Professore Associato

1986: Bachelor Degree in Physical Education; 1989: Degree in Biology; 1989-94: Research Fellow, Inst. of Anatomy, Dept. of Cytometry, Univ. Bologna. He won 2 scientific awards (1990 and 1992) at the Italian Group of Cytometry Congress; 1994: Degree in Pharmacy; 1998: Ph.D. in Human Morphological Sciences, Univ. Bologna, project on "NK cell differentiation", developed at the Jefferson Univ., Philadelphia during the period 1995-1998 under the supervision of Dr. Bice Perussia. 1998-2001: University Research Position, 2001-present; Associate Professor of the Univ. of Urbino. Invited speaker at: 1. several courses of National School of Cytometry, 2. European School of Flow Cytometry, 3. Advanced School of Oncology and Medical Science, 4. Conferences of GIC (Italian Group of Cytometry), 5.Euroconference on Clinical Cytometry: from pathogenesis to therapy, 6. Course of SIBioC society, 7. Conference and Courses of the international society ESCCA. Chairmen at XXII Congress of the ISAC (International Society for Advancement of Cytometry), Cell Death III session, Montpellier 2004, and at the Conferences of GIC 2007. Coordinator and speaker at National School of Cytometry, “Hematopoietic Stem Cells: clinical and experimental applications”. 2004-2007 part of the Education Task Force of ISAC, 2007-2013 and 2016-2021 part the executive council of GIC. From 2005 Principal Investigator of the experiment called CRYOSTEM at the Gran Sasso National Laboratory (LNGS), from 2006 to 2007 Principal Investigator of CRIORAD project for the National Institute of Nuclear Physics (INFN) LNGS unit, and from 2009 to 2011 of EXCALIBUR project. From 2005 is associated with INFN-LNGS . REFEREE FOR JOURNALS: Cytometry, Cells, British Journal of Pharmacology, BioMed Central Cell Biology and CIVR (Commettee for valuation of italian research). RESEARCH INTERESTS: Renin-angiotensin System, NK Cell Biology and Differentiation, Viral Infections, Evolution, Cytokines, Hematopoiesis, Cell Cycle, Apoptosis, Ionising Radiation, Flow Cytometry. Author of 79 full length papers.

1986: Diploma dell’Istituto Superiore di Educazione Fisica; 1989: Laurea in Biologia; 1989-94: Interno laureato, Ist. di Anatomia, Centro di Citometria, Univ. Bologna. Ha vinto 2 premi scientifici (1990 e 1992) al Congresso del Gruppo Italiano di Citometria; 1994: Laurea in Farmacia; 1998: Ph.D. in Scienze Morfologiche Umane, Univ. Bologna, progetto: NK cell differentiation, svolto alla Jefferson Univ., Filadelfia durante il periodo 1995-1998 sotto la guida della Dr. Bice Perussia. Nel 1998 Ricercatore Universitario, dal 2001 Professore Associato all’Univ. Di Urbino. Speaker su invito a: 1. vari corsi della Scuola Nazionale di Citometria, 2. European School of Flow Cytometry, 3. Advanced School of Oncology and Medical Science, 4. Conferenze Nazionali del GIC (gruppo italiano di Citometria), 5. Euroconference on Clinical Cytometry: from pathogenesis to therapy, 6. Corso della società SIBioC, 7. Conferenza e Corsi della società scientifica internazionale ESCCA. Moderatore al XXII congresso internazionale dell’ISAC (International Society for Advancement of Cytometry), Montpellier 2004, sessione “Cell Death III” ed alla Conferenza Nazionale di citometria, 2007. Coordinatore del Corso teorico-pratico di formazione ed aggiornamento “Cellule staminali emopoietico: applicazioni cliniche e sperimentali”, Scuola Nazionale di Citometria.  2004-2007 ha fatto parte della Education Task Force dell’ISAC, dall’ottobre 2007 al 2013 e nuovamente dal 2016 al 2021 ha fatto parte del Consiglio Direttivo della Società Scientifica GIC. Dal 2005 è responsabile dell'esperimento CRYOSTEM presso i Laboratori Nazionali del Gran Sasso (LNGS), dal 2006 al 2007 è stato responsabile locale per l'Istituto Nazionale di Fisica Nucleare (INFN) dei LNGS dell'esperimento CRIORAD e dal 2009 al 2011 per l'esperimento EXCALIBUR. Dal 2005 è associato all'INFN dei LNGS. REFEREE per le RIVISTE: Cytometry, Cancer Research, British Journal of Haematology, BioMed Central Cell Biology e per il CIVR. INTERESSI SCIENTIFICI: Biologia e Differenziamento delle Cellule NK, Infezioni virali, Evoluzione, Citochine, Emopoiesi, Ciclo Cellulare, Apoptosi, Radiazioni Ionizzanti, Citometria a flusso. Autore di 79 lavori in extenso.

67. Understanding the Synergy of NKp46 and Co-Activating Signals in Various NK Cell Subpopulations: Paving the Way for More Successful NK-Cell-Based Immunotherapy.

Zamai L, Del Zotto G, Buccella F, Gabrielli S, Canonico B, Artico M, Ortolani C, Papa S.

Cells. 2020;9(3):753.

68. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients.

Zamai L.

Cells. 2020 Jul 16;9(7):1704.

69. Unveiling Human Non-Random Genome Editing Mechanisms Activated in Response to Chronic Environmental Changes: I. Where Might These Mechanisms Come from and What Might They Have Led To?

Zamai L.

Cells. 2020;9(11):2362

70. The role of inflammation in diabetic retinopathy: a review.

Taurone S, Ralli M, Nebbioso M, Greco A, Artico M, Attanasio G, Gharbiya M, Plateroti AM, Zamai L, Micera A.

Eur Rev Med Pharmacol Sci. 2020;24(20):10319-10329.

71. Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients.

Zamai L.

Cells. 2021 Feb 27;10(3):506. doi: 10.3390/cells10030506.

72. ESCCABase project: A repository in progress.

Ortolani C, D'Atri M, Zamai L, Canonico B, Del Zotto G, Papa S.

Cytometry A. 2021 Jul;99(7):659-663. doi: 10.1002/cyto.a.24355.

73. Lock, Stock and Barrel: Role of Renin-Angiotensin-Aldosterone System in Coronavirus Disease 2019.

Zanza C, Tassi MF, Romenskaya T, Piccolella F, Abenavoli L, Franceschi F, Piccioni A, Ojetti V, Saviano A, Canonico B, Montanari M, Zamai L, Artico M, Robba C, Racca F, Longhitano Y.

Cells. 2021 Jul 11;10(7):1752. doi: 10.3390/cells10071752.

74. Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?

Montanari M, Canonico B, Nordi E, Vandini D, Barocci S, Benedetti S, Carlotti E, Zamai L.

Adv Biol Regul. 2021 Aug;81:100820. doi: 10.1016/j.jbior.2021.100820.

75. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.

Zamai L, Rocchi MBL.

Br J Pharmacol. 2022 Jan;179(2):218-226. doi: 10.1111/bph.15620.

76. Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19.

Ciofalo A, Cavaliere C, Masieri S, Di Chicco A, Fatuzzo I, Lo Re F, Baroncelli S, Begvarfaj E, Adduci A, Mezzaroma I, Mastroianni CM, de Vincentiis M, Greco A, Zamai L, Artico M..

Cells. 2022 Feb 24;11(5):788. doi: 10.3390/cells11050788.

77. Fluorescent Silica Nanoparticles Targeting Mitochondria: Trafficking in Myeloid Cells and Application as Doxorubicin Delivery System in Breast Cancer Cells.

Sola F, Montanari M, Fiorani M, Barattini C, Ciacci C, Burattini S, Lopez D, Ventola A, Zamai L, Ortolani C, Papa S, Canonico B.

Int J Mol Sci. 2022 Mar 12;23(6):3069. doi: 10.3390/ijms23063069.

78. Hypothesis: Efficacy of early treatments with some NSAIDs in COVID-19: Might it also depend on their direct and/or indirect zinc chelating ability?

L. Zamai.

Br J Pharmacol. 2023 Feb;180(3):279-286. doi: 10.1111/bph.15989.

79. Circulating ACE2 level and zinc/albumin ratio as potential biomarkers for a precision medicine approach to COVID-19.

Benedetti S, Sisti D, Vandini D, Barocci S, Sudano M, Carlotti E, Teng JLL, Zamai L.

Adv Biol Regul. 2023 Aug;89:100973. doi: 10.1016/j.jbior.2023.100973.